Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin | Zendy

Yao-Yu Hsieh | Zendy; ChuehChuan Yen | Zendy; ChunNan Yeh | Zendy; Chin-Yuan Tzen | Zendy; Liu H | Zendy; Hui-Ju Lee | Zendy; HaoWei Teng | Zendy; ChengHwai Tzeng | Zendy; Tzeon-Jye Chiou | Zendy; TaChung Chao | Zendy

Open Access

Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin

Author(s) -

Yao-Yu Hsieh,

ChuehChuan Yen,

ChunNan Yeh,

Chin-Yuan Tzen,

Liu H,

Hui-Ju Lee,

HaoWei Teng,

ChengHwai Tzeng,

Tzeon-Jye Chiou,

TaChung Chao

Publication year - 2011

Publication title -

journal of the chinese medical association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.535

H-Index - 42

eISSN - 1728-7731

pISSN - 1726-4901

DOI - 10.1016/j.jcma.2011.04.007

Subject(s) - medicine , imatinib , stromal tumor , exon , cancer research , salvage therapy , oncology , imatinib mesylate , stromal cell , chemotherapy , gene , myeloid leukemia , genetics , biology

Here we presented a 60-year-old Taiwanese man with advanced gastrointestinal stromal tumor. Disease progression was noted during imatinib treatment. Surgical resection was done and mutation analysis of KIT gene in all the resected tumors revealed deletion mutations of codons 558-565 in exon 11, whereas a missense mutation was also identified at codon 822 in exon 17 in one resected tumor. Patient's disease was refractory to escalating dose of imatinib and dasatinb. Surprisingly, combination of imatinib with pegylated liposomal doxorubicin produced a substantial response and resulted in a 5-month progression free period for this imatinib-resistant gastrointestinal stromal tumor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research